Cardiac Toxicities of Cancer Therapies: From Traditional Agents to Emerging Targets in Cardio-Oncology
- 13 October 2025
- journal article
- review article
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 19 (1) , 25
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Prevention and Management of Cardiotoxicity Secondary to Thoracic Radiation2024
- Atorvastatin for Anthracycline-Associated Cardiac DysfunctionJAMA, 2023
- New Insights into the Understanding of Mechanisms of Radiation-Induced Heart DiseaseCurrent Treatment Options in Oncology, 2023
- Myocardial work—A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced‐cardiotoxicity in hematological patientsJournal of Clinical Ultrasound, 2022
- Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidityHematological Oncology, 2020
- Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and ManagementCurrent Oncology Reports, 2020
- Cardiotoxicities of 5-Fluorouracil and Other FluoropyrimidinesCurrent Treatment Options in Oncology, 2020
- Personalized Approach to Cancer Treatment–Related CardiomyopathyCurrent Heart Failure Reports, 2020
- Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast CancerCurrent Breast Cancer Reports, 2017
- Anthracycline Chemotherapy and CardiotoxicityCardiovascular Drugs and Therapy, 2017